ALVR

Companies
NASDAQ
AlloVir Inc.
Health Care
Price Chart
Overview

About ALVR

AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

Market Cap
$86.5M
Volume
44.8K
Avg. Volume
44.0K
P/E Ratio
-30.656252
Dividend Yield
0.00%
Employees
121.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.09
Moderate Correlation
Volatility
High (0.84)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for ALVR.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, ALVR shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$86.5M
Volume44.8K
P/E Ratio-30.66
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
August 9, 2024

PortfolioPilot Analysis

Get AI-powered insights on how ALVR fits into your investment strategy and portfolio diversification.

Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025